Shanghai Kejun Pharmaceutical Technology

Shanghai Kejun Pharmaceutical Technology is a biotechnology company headquartered in Shanghai, China, dedicated to the development of innovative targeted protein degradation (TPD) therapies. The company utilizes a proprietary platform to design and optimize small molecule degraders, including Proteolysis-Targeting Chimeras (PROTACs) and molecular glues, specifically targeting proteins previously considered undruggable. Founded by Dr. Jun Qin, an expert in proteomics, Kejun integrates advanced mass spectrometry and structural biology into its drug discovery process. Its primary therapeutic focus lies in oncology and immunology, with a pipeline of early-stage programs aimed at hematological malignancies and solid tumors. The company has secured significant backing from prominent venture capital firms to advance its research and development initiatives.